Emerging Therapies in Rheumatoid Arthritis

Pharmacor -- June 2007

  Introduction:

In the late 1990s, the rheumatoid arthritis (RA) market was transformed by the emergence of tumor necrosis-alpha (TNF-alpha) inhibitors. The RA market is now entering a new phase of growth as several novel biological agents are set to launch. These agents will enter a market characterized by still-plentiful opportunity but also fierce competition and a challenging reimbursement environment.

  Questions Answered in This Report:

Several novel biological agents will emerge in the next fifteen years. Which of these agents will capture the greatest market share, and what are the keys to their success?

We forecast that the TNF-alpha inhibitors will continue to dominate the market throughout the fifteen-year forecast period. Why will these agents remain dominant in the face of increasing competition from novel biologics?

Thought-leading physicians tell us that they want greater access to effective, innovative treatments for their RA patients. What are the barriers to greater access to effective therapies? Will changes in the market allow earlier access to innovative therapies?

  Scope:

Markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 46 country-specific interviews with thought-leading rheumatologists.

Epidemiology: Prevalence of rheumatoid arthritis.

Emerging therapies: Phase II: 21 drugs; Phase III/PR: 5 drugs; registered: 0 drugs. Coverage of 25 select preclinical and Phase I products.

Market forecast features: The market forecast covers a fifteen-year period, and sales are forecast for 2006, 2011, 2016, and 2021.